Table. Nucleotide and amino acid changes in viral protein 1 over time in immunodeficiency-related vaccine-derived poliovirus isolated from the stools of a severe combined immune deficiency patient, Israel, October 2015–August 2016.
| Sabin 2 sequence | Immunodeficiency-related vaccine-derived poliovirus type 2 isolate number Approximate number of days after last trivalent oral poliovirus vaccine |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | ||
| 119 | 172 | 200 | 247 | 292 | 334 | 382 | 409 | ||
| Position | Nt | Nt substitutionsa | |||||||
| 10 | G | None | None | None | None | None | None | None | T |
| 26 | C | T | T | T | T | T | T | T | T |
| 40 | A | G | G | G | G | G | G | G | G |
| 44 | A | None | None | None | G | G | G | G | G |
| 55 | G | None | None | None | None | R | None | None | None |
| 81 | G | None | None | None | A | R | R | None | None |
| 103 | C | None | None | None | None | None | None | T | None |
| 117 | G | A | A | A | A | A | A | A | A |
| 288 | None | None | None | None | None | None | None | R | |
| 308 | G | A | A | A | A | A | A | A | A |
| 364 | C | T | T | T | T | T | T | T | T |
| 405 | T | None | None | None | None | None | Y | None | None |
| 428b | T | C | C | C | C | C | C | C | C |
| 459 | A | None | None | None | None | None | R | G | G |
| 486 | C | None | None | None | T | T | T | T | T |
| 501 | T | None | None | None | None | None | Y | None | None |
| 516 | C | T | T | T | T | T | T | T | T |
| 540 | C | None | None | None | None | Y | Y | None | None |
| 600 | A | None | None | None | None | None | W | None | None |
| 660 | A | None | None | None | None | None | None | R | None |
| 769 | A | G | G | G | G | G | G | G | G |
| 849 | T | A | A | A | A | A | A | A | A |
| Total Nt changes | 9 | 9 | 9 | 12 | 14 | 17 | 14 | 14 | |
| Position |
AA
(codon) |
AA substitutions
(codona) |
|||||||
| 4 | D (GAC) |
None | None | None | None | None | None | None | Y (TAC) |
| 9 | A (GCC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
| 14 | T (ACT) |
A (GCT) |
A (GCT) |
A (GCT) |
A (GCT) |
A (GCT) |
A (GCT) |
A (GCT) |
A (GCT) |
| 15 | K (AAA) |
None | None | None | R (AGA) |
R (AGA) |
R (AGA) |
R (AGA) |
R (AGA) |
| 19 | V (GTT) |
None | None | None | None | I/V (RTT) |
None | None | None |
| 35 | P (CCA) |
None | None | None | None | None | None | S (TCA) |
None |
| 103 | R (AGA) |
K (AAA) |
K (AAA) |
K (AAA) |
K (AAA) |
K (AAA) |
K (AAA) |
K (AAA) |
K (AAA) |
| 143b | I (ATT) |
T (ACT) |
T (ACT) |
T (ACT) |
T (ACT) |
T (ACT) |
T (ACT) |
T (ACT) |
T (ACT) |
| 257 | I (ATC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
V (GTC) |
| Total amino acid changes | 5 | 5 | 5 | 6 | 7 | 6 | 7 | 7 | |
AA: amino acid; Nt: nucleotide.
Cells in green represent transitory nt or inferred amino acid substitutions while cells in yellow indicate substitutions that persist in all subsequent isolates. When a mutation is first detected in the latest isolate obtained, the cell is not shaded as it is remains to be seen whether this mutation will be found in further isolates.
a R = A and G; Y = C and T; W = A and T.
b Neurovirulence attenuation site.